| Autor: |
Rhian Siân, Davies, Christian, Smith, Michael Robert, Button, Jacob, Tanguay, Jim, Barber, Nachiappan, Palaniappan, John, Staffurth, Jason Francis, Lester |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Anticancer research. 35(10) |
| ISSN: |
1791-7530 |
| Popis: |
Several treatments have been shown to prolong survival in metastatic castrate-resistant prostate cancer (mCRPC); the optimum sequencing of these is not established. We investigated methods of identifying patients with mCRPC unlikely to respond to abiraterone.A retrospective analysis was carried-out in 47 consecutive patients with mCRPC treated sequentially with androgen deprivation (LHRHa), bicalutamide, docetaxel then abiraterone.The median progression-free survival in patients treated with abiraterone was shorter in those with ≤18 months' response to LHRHa (118 vs. 279 days; p=0.018), bicalutamide non-responders (91 vs. 196 days; p=0.003) and patients with ≤6 months' response to docetaxel (102 vs. 294 days; p0.001). The median overall survival was also shorter (348 vs. 815 days, p=0.016; 413 vs. 752 days, p=0.009; and 325 vs. 727 days, p0.04, respectively).A response of ≤18 months' to LHRHa, non-response to bicalutamide and ≤6 months' response to docetaxel predicted poor response to abiraterone. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
